279 related articles for article (PubMed ID: 37376552)
1. Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies.
Kaewchim K; Glab-Ampai K; Mahasongkram K; Saenlom T; Thepsawat W; Chulanetra M; Choowongkomon K; Sookrung N; Chaicumpa W
Viruses; 2023 May; 15(6):. PubMed ID: 37376552
[TBL] [Abstract][Full Text] [Related]
2. A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529).
Lu Y; Li Q; Fan H; Liao C; Zhang J; Hu H; Yi H; Peng Y; Lu J; Chen Z
Int J Nanomedicine; 2023; 18():353-367. PubMed ID: 36700149
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
4. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
5. Deep mutational engineering of broadly-neutralizing nanobodies accommodating SARS-CoV-1 and 2 antigenic drift.
Laroche A; Orsini Delgado ML; Chalopin B; Cuniasse P; Dubois S; Sierocki R; Gallais F; Debroas S; Bellanger L; Simon S; Maillère B; Nozach H
MAbs; 2022; 14(1):2076775. PubMed ID: 35593235
[TBL] [Abstract][Full Text] [Related]
6. Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies.
Güttler T; Aksu M; Dickmanns A; Stegmann KM; Gregor K; Rees R; Taxer W; Rymarenko O; Schünemann J; Dienemann C; Gunkel P; Mussil B; Krull J; Teichmann U; Groß U; Cordes VC; Dobbelstein M; Görlich D
EMBO J; 2021 Oct; 40(19):e107985. PubMed ID: 34302370
[TBL] [Abstract][Full Text] [Related]
7. Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters.
Aksu M; Kumar P; Güttler T; Taxer W; Gregor K; Mußil B; Rymarenko O; Stegmann KM; Dickmanns A; Gerber S; Reineking W; Schulz C; Henneck T; Mohamed A; Pohlmann G; Ramazanoglu M; Mese K; Groß U; Ben-Yedidia T; Ovadia O; Fischer DW; Kamensky M; Reichman A; Baumgärtner W; von Köckritz-Blickwede M; Dobbelstein M; Görlich D
Antiviral Res; 2024 Jan; 221():105778. PubMed ID: 38065245
[TBL] [Abstract][Full Text] [Related]
8. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
9. Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models.
Han Q; Wang S; Wang Z; Zhang C; Wang X; Feng N; Wang T; Zhao Y; Chi H; Yan F; Xia X
Virol Sin; 2023 Oct; 38(5):787-800. PubMed ID: 37423308
[TBL] [Abstract][Full Text] [Related]
10. Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2.
Rao X; Zhao R; Tong Z; Guo S; Peng W; Liu K; Li S; Wu L; Tong J; Chai Y; Han P; Wang F; Jia P; Li Z; Zhao X; Li D; Zhang R; Zhang X; Zou W; Li W; Wang Q; Gao GF; Wu Y; Dai L; Gao F
Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2314193120. PubMed ID: 38109549
[TBL] [Abstract][Full Text] [Related]
11. Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein.
Su Q; Shi W; Huang X; Wan Y; Li G; Xing B; Xu ZP; Liu H; Hammock BD; Yang X; Yin S; Lu X
Cells; 2022 Oct; 11(21):. PubMed ID: 36359751
[TBL] [Abstract][Full Text] [Related]
12. Generation and Characterization of a Nanobody Against SARS-CoV.
Li JF; He L; Deng YQ; Qi SH; Chen YH; Zhang XL; Hu SX; Fan RW; Zhao GY; Qin CF
Virol Sin; 2021 Dec; 36(6):1484-1491. PubMed ID: 34403037
[TBL] [Abstract][Full Text] [Related]
13. Hybrid Proteins with Short Conformational Epitopes of the Receptor-Binding Domain of SARS-CoV-2 Spike Protein Promote Production of Virus-Neutralizing Antibodies When Used for Immunization.
Karyagina AS; Gromov AV; Grunina TM; Lyaschuk AM; Poponova MS; Kleymenov DA; Strukova NV; Generalova MS; Ryazanova AV; Galushkina ZM; Dobrynina OY; Bolshakova TN; Sergeeva MV; Romanovskaya-Romanko EA; Krasilnikov IV; Subbotina ME; Lunin VG
Biochemistry (Mosc); 2022 Apr; 87(4):319-330. PubMed ID: 35527370
[TBL] [Abstract][Full Text] [Related]
14. Structure basis of two nanobodies neutralizing SARS-CoV-2 Omicron variant by targeting ultra-conservative epitopes.
Sun Z; Wang L; Li L; Sun Y; Zhang D; Zhou S; Li Y; Li X; Qiao H; Cui Q; Lan Z; Meng X; Xu J; Geng Y; Dai Y
J Struct Biol; 2023 Sep; 215(3):107996. PubMed ID: 37419228
[TBL] [Abstract][Full Text] [Related]
15. A potent neutralizing nanobody targeting a unique epitope on the receptor-binding domain of SARS-CoV-2 spike protein.
Zhang Y; Wang D; Xiang Q; Hu X; Zhang Y; Wu L; Zhang Z; Wang Y; Zhao J; McCormick PJ; Fu J; Fu Y; Zhang J; Jiang H; Li J
Virology; 2024 Jan; 589():109925. PubMed ID: 37984151
[TBL] [Abstract][Full Text] [Related]
16. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
[TBL] [Abstract][Full Text] [Related]
17. Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron.
Ma H; Zhang X; Zheng P; Dube PH; Zeng W; Chen S; Cheng Q; Yang Y; Wu Y; Zhou J; Hu X; Xiang Y; Zhang H; Chiu S; Jin T
Cell Res; 2022 Sep; 32(9):831-842. PubMed ID: 35906408
[TBL] [Abstract][Full Text] [Related]
18. Structural basis of nanobodies neutralizing SARS-CoV-2 variants.
Shi Z; Li X; Wang L; Sun Z; Zhang H; Chen X; Cui Q; Qiao H; Lan Z; Zhang X; Li X; Li L; Xu J; Gong R; Fan C; Geng Y
Structure; 2022 May; 30(5):707-720.e5. PubMed ID: 35276082
[TBL] [Abstract][Full Text] [Related]
19. A Novel Conserved Linear Neutralizing Epitope on the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein.
Hua RH; Zhang SJ; Niu B; Ge JY; Lan T; Bu ZG
Microbiol Spectr; 2023 Aug; 11(4):e0119023. PubMed ID: 37306579
[TBL] [Abstract][Full Text] [Related]
20. Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron.
Casasnovas JM; Margolles Y; Noriega MA; Guzmán M; Arranz R; Melero R; Casanova M; Corbera JA; Jiménez-de-Oya N; Gastaminza P; Garaigorta U; Saiz JC; Martín-Acebes MÁ; Fernández LÁ
Front Immunol; 2022; 13():863831. PubMed ID: 35547740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]